MALARIA,FALCIPARUM

This early-stage trial tests a new malaria vaccine (PfSPZ-LARC2) in 58 healthy adults who have never had malaria. The vaccine uses weakened malaria parasites that stop growing in the liver and cannot cause blood infection. Researchers will check if it is safe and if it protects a…

This study tests a new malaria vaccine designed to target the parasite at different stages of its life cycle. Researchers will give the vaccine to 56 healthy adults (18-35 years) and children (5-17 months) in Burkina Faso to check its safety and how well it triggers an immune res…

This study tests a new way to find and treat a type of malaria (P. vivax) that can hide in the liver and come back months later. Researchers will use a simple blood test to find people who have been infected recently, then give them a treatment to clear the hidden parasites. The …

This study will give a combination of two malaria drugs (dihydroartemisinin-piperaquine and primaquine) to entire communities in Ghana every two months for two years. The goal is to see if this approach can reduce the number of people carrying malaria parasites, even those with n…

This early-stage trial tests whether two new long-acting injectable drugs, MMV055 and MMV371, are safe and how they work in the body. Up to 72 healthy adults will receive one or two shots and be monitored for up to 48 weeks. The goal is to find a dose that could one day prevent m…

This early-stage study will check if a new experimental drug for malaria, called GSK3772701, changes how the body processes other medications. Twenty healthy adults aged 18 to 55 will take both GSK3772701 and a common probe drug called midazolam. The goal is to see if GSK3772701 …